meta-analyses of randomized controlled trials (RCTs) of salt reduction and BP have been undertaken. 8, 9 Although these analyses consistently report a reduction in the level of BP with reduced salt intake, the level of BP achieved is less impressive in the longer term. A Cochrane review of RCTs of dietary salt restriction intervention of at least 6 months duration found that intensive support and encouragement to reduce salt intake lowered BP at 13 to 60 months but only by a small amount (systolic by 1.1 mm Hg, 95% CI: 1.8-0.4, diastolic by 0.6 mm Hg, 95% CI: 1.5 to −0.3). 10 The reduction in BP appeared larger for people with higher BP. A decrease in BP is only important if it results in a decrease in CVD events and deaths. Sustained reductions in mean BP of 2-3 mm Hg are necessary for important population reductions in CVD events. 11 Whereas the Cochrane review also sought to assess the impact of dietary salt restriction on mortality and CVD events, across the included 11 RCTs there were only 17 deaths spread evenly across groups and 46 CVD events in the controls compared with 36 in low-sodium diet groups. This extremely low number of events substantially limited the ability of this review to detect small to moderate reductions in the risk of CVD events.
The aim of this study was to undertake an updated systematic review and a meta-analysis of RCT evidence to confirm whether a reduction in dietary salt is associated with improvements in mortality and CVD events.
methodS
The study was carried out according to the methods recommended by the Cochrane Collaboration and written in accordance with the PRISMA statement for reporting systematic reviews. 12, 13 Search strategy. We searched several clinical databases up to October 2008: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO, Health Technology Assessment (HTA), Abstracts of Reviews of Effects (DARE), and the NHS Centre for Reviews and Dissemination (CRD) databases. Consideration was given to variations in terms used and spellings of terms so that studies were not missed and took the general form: ("salt" OR "sodium" OR (synonyms)) and ("CVD" or (synonyms)). Searches included a filter to limit to humans and controlled trials. No language or additional limits were included. An updated search of MEDLINE, EMBASE, and CENTRAL was undertaken (to March 2011). Reference lists of reviews and included articles were also examined for additional studies.
Inclusion criteria. Studies were selected for inclusion on the basis of the following criteria:
• Study design: RCTs (individual or cluster level allocation)
with follow-up of at least 6 months. • Types of participants: adults (18 years or older), irrespective of gender or ethnicity. Studies of children or pregnant women were excluded.
• Intervention: reduced dietary salt and could include studies that involved participants receiving a dietary intervention that restricted salt or studies where the intervention was advised to reduce salt intake. • Comparator: control or placebo diet, or no intervention. • Outcomes: Primary mortality (overall and CVD), CVD morbidity (including fatal and nonfatal myocardial infarction, stroke, angina, heart failure, peripheral vascular events, sudden death, revascularization (coronary artery bypass surgery or angioplasty with or without stenting) and CVD-related hospital admissions. In studies that reported primary outcomes, we also sought the following secondary outcomes: systolic and diastolic BP, and urinary salt excretion (or other method of estimation of salt intake) and health-related quality of life using a validated outcome measure (e.g., Short Form 36 (ref . 14)).
Studies not reporting all-cause mortality or CVD events were excluded.
Selection of studies. The titles and abstracts of studies identified by the search strategy were independently screened by two reviewers (K.E.A. and R.S.T.) and clearly irrelevant studies discarded. In order to be selected, abstracts had to clearly identify the study design, an appropriate population and a relevant intervention/exposure, as described above. The full-text reports of all potentially relevant studies were obtained and assessed independently for eligibility, based on the defined inclusion criteria, by two reviewers (K.E.A. and R.S.T.). Any disagreement was resolved by discussion or, where agreement could not be reached, by consultation with an independent third person (L.H.).
Data extraction and management. Standardized data extraction forms were used. Relevant data regarding inclusion criteria (study design, participants, intervention/exposure, and outcomes), risk of bias (see below) and outcome data were extracted. Data extraction was carried out by a single reviewer (K.E.A. or R.S.T.) and checked by a second reviewer (R.S.T. or K.E.A.). Disagreements were resolved by discussion or if necessary by a third reviewer (L.H.). We extracted outcomes at the last reported follow-up point within the trial, and also at the latest follow-up after the trial, where this was available; we reasoned this would maximize the number of events reported. Included study authors were contacted to clarify any missing outcome data or issues of risk of bias assessment.
Assessment of risk of bias in included studies.
We assessed a number of risk of bias domains in studies meeting the inclusion criteria: random sequence generation and allocation concealment, description of dropouts and withdrawals, blinding (participants, personnel, and outcome assessment) and selective outcome reporting. 12 In addition, evidence was sought that the groups were balanced at baseline, that intention-to-treat analysis was undertaken and whether the period over which the salt
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Data synthesis. For mortality and CVD events, a relative risk (RR) and 95% CI was calculated for each trial. For BP and urinary sodium excretion, mean group difference and 95% CI were calculated using weighted mean difference. Heterogeneity amongst included studies was explored qualitatively (by comparing the characteristics of included studies), and quantitatively (using the χ 2 test of heterogeneity and I 2 statistic). 15, 16 Results from included studies were combined for each outcome to give an overall estimate of treatment effect at the latest point available within the randomized trial, and, as a secondary analysis, at the latest point available (including where participants were followed after the end of the randomization period). A fixed-effect meta-analysis was used except where statistical heterogeneity (χ 2 P value ≤0.05 and I 2 value ≥50%) was identified, in which case methodological and clinical reasons for heterogeneity were considered and a random-effects model was used.
We planned to explore various potential moderator effects (i.e., individual advice vs. population level interventions, level of baseline risk of CVD, salt reduction only interventions vs. multicomponent dietary interventions that include salt restriction, level of salt reduction achieved, baseline BP, and change in BP). 17 Additionally, we planned to use funnel plot and Egger et al. 's regression test for funnel plot asymmetry to examine the likely presence of publication bias and small-study effect. 18 However, an insufficient number of included studies prevented us from undertaking these analyses.
Analyses were done using the Review Manager (RevMan) software, version 5.0 (The Cochrane Collaboration, Nordic Cochrane Centre, Copenhagen, Denmark).
reSultS

Study characteristics
Selection of studies is summarized in Figure 1 . The characteristics of the seven included trials are summarized in Table 1 . These trials were published in 39 papers. We included three trials in normotensives (HPT 20 , TOHP I 33, 34 , TOHP II 34, 45 ; n = 3,518), two in hypertensives (Morgan et al. 30 , TONE 51 ; n = 758), and one in a mixed population of normo-and hypertensives (Chang et al. 19 ; n = 1,981). The normotensive trials were in healthy individuals (predominantly white men, median age 40 years) with high-normal BP and all conducted in the USA. The three studies in hypertensive populations included one trial in treated hypertensives, two in participants with untreated hypertension (predominantly male, median age 66 years and mix of ethnicities) and were conducted in Australia, Taiwan, and USA. Sixty percent of participants in the Chang et al. study were defined as nonhypertensive. 19 The final trial was undertaken in Italy and included participants diagnosed with heart failure (ethnicity not reported, mean age 73 years) who had been hospitalized for uncompensated heart failure within the previous 30 days and had a high-normal BP. 32 Trial follow-up ranged across studies from 6 to 71 months postrandomization. A longer observational follow-up following the end of the randomized trial period was reported for the TOHP I (11.5 years) 34 and TOHP II (8 years) 34 trials and we were able to obtain longer observational unpublished data from the authors of the TONE study (12.7 years).
Six of the seven trials aimed to reduce salt intake by a range of approaches that included comprehensive dietary and behavior change programs led by experienced personnel, including group counseling sessions, various types of advice and the provision of information leaflets. Intervention-group sodium excretion goals were set at <70-100 mmol/24 h. Control groups received no active behavioral intervention or advice. In contrast, in the Chang et al. study, 19 participants received a dietary program according to the cook of the kitchen to which they were assigned (cluster randomization) and were given either "high potassium salt" (low sodium) or "usual salt" (high sodium) diet. Intervention duration ranged across studies from 6 to 36 months. In the Paterna trial of patients with heart failure, in addition to either low-sodium or control diet, both groups received a high-dose diuretic (furosemide, 250-500 mg b.i.d.). 32
risk of bias in included studies
A number of studies failed to give sufficient detail to assess their potential risk of bias. Details of generation and concealment of random allocation sequence were particularly poorly reported ( Table 2) . However, in all cases there was objective 
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Dietary Salt and Cardiovascular Disease evidence of balance in baseline characteristics of intervention and control participants. While studies reported loss to follow-up and reasons for this loss, few undertook analyses to assess the impact of these losses. In the TONE study, the authors state that data was collected via psychological questionnaires at randomization and a number of the follow-up visits. However, none of these data were found in the identified trial reports. [51] [52] [53] [54] [55] [56] [57] Although often not stated, all studies appeared to undertake an intention-to-treat analysis in that groups were analyzed according to initial random allocation. All studies assessed compliance with salt reduction intervention using diet diaries or monitoring urinary salt excretion. However, in the longer-term follow-up of the TOHP I, TOHP II, and TONE trials such compliance data were not reported. Therefore, it was unclear if intervention groups were encour-aged to continue their low-salt diets or to return to their pretrial diet. Similarly, control groups may have been left to continue with their usual diet or advised to reduce their salt at the end of the trial.
mortality and cvd events
Results are presented and pooled separately for normotensive, hypertensive, and heart failure studies. Outcomes were pooled at end of trial and at longest follow-up point. All-cause mortality was reported at the end of the trial in six of the included studies (HPT 20 ; TOHP I 33 ; TOHP II 45 ; Chang et al. 19 ; Morgan et al. 30 , and Paterna et al. 32 ). Although there was weak evidence of a reduction in the number of deaths in the reduced salt group relative to controls for normotensives (fixed effects, RR 0.67, 95% CI: 0.40-1.12, 60 deaths in 32 (see Figure 2 ).
In the three trials (TOHP I 33, 34 , TOHP II 34, 45 , and TONE 51 ) with long-term follow-up which increased the total number of events available for analysis, there was still no strong evidence of a reduction in the number of deaths in the reduced salt group relative to controls, for the normotensives (fixed effects, RR 0.90, 95% CI: 0.58-1.40, 79 deaths, χ 2 P value = 1.00, I 2 = 0%) or hypertensive populations (fixed effects, RR 0.96, 95% CI: 0.83-1.11, 565 deaths, χ 2 P value = 0.92, I 2 = 0%) (see Figure 3 ).
CVD mortality was only reported in two studies of hypertensive patients. Both studies only reported trial end data. Chang et al. reported a lower proportion of CVD deaths in the reduced salt group (27 died; 1,310.0/100,000 person years) than in the control group (66 died; 2,140/100,000 person years). 19 Morgan et al. reported only five CVD deaths: three in the intervention group and two in the control group. 30 The pooled RR was consistent with more than a halving of the RR of CVD deaths or a small increase (fixed effects, RR 0.69, 95% CI: 0.45-1.05, 98 CVD deaths, χ 2 P value = 0.26, I 2 = 0%) (see Figure 4 ). 
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Overall CVD morbidity was available for four trials (TOHP I 33, 34 , TOHP II, Morgan et al. 30 , and TONE 51 ). There was some evidence of statistical heterogeneity which may reflect that the definition of CVD morbidity varied between trials, although it broadly consisted of a composite of myocardial infarction, stroke, coronary artery bypass, angioplasty, or death from a CVD cause. At longer-term observational followup, TOHP I reported a RR reduction of CVD events of 49% (95% CI: 9-71%) with reduced salt although when pooled with long-term observational follow-up of TOHP II there was no strong evidence of benefit in normotensive participants (random effects, RR: 0.71, 95% CI: 0.42-1.20, 200 events, χ 2 P value = 0.10; I 2 = 63%). 34 There were no reports of CVD morbidity during or at the end of the randomized period for TOHP I or II studies. We found no strong evidence of benefits of salt reduction in hypertensive individuals (fixed effects, RR: 0.84, 95% CI: 0.57-1.24, 93 events, χ 2 P value = 0.53; I 2 = 0%) at end of trial (see Figure 5 ).
Individual CVD morbidity outcomes were infrequently reported and at trial end only. Paterna et al. reported 39 CVDrelated hospital admissions (30 intervention, 9 control) in their study of congestive heart failure patients. 32 In TONE, at trial end, three patients experienced strokes (1 intervention, 2 control); 6 experienced a myocardial infarction (2 intervention, 4 control); 3 developed heart failure (2 intervention, 1 control), and 26 suffered from angina (9 intervention, 17 control). 51 
Blood pressure
End of trial BP was reported by all studies except Chang et al. 19 There was a evidence of substantial statistical heterogeneity. Systolic BP was reduced in all intervention arms of trialsnormotensives (random effects, mean difference: 6 and 7) .
urinary sodium excretion
Changes in urinary sodium excretion at the end of trial were reported by all studies except Chang et al. 19 There was some evidence of statistical heterogeneity which may reflect different approaches to the assessment of 24-h urinary sodium excretion. In the study by Morgan et al., results were only reported as samples and therefore contain repeated observations for a number of patients. 30 As for BP, in a number of studies, the last urinary sodium excretion available was at a time point much preceding the timing of the report mortality or CVD events (BP follow-up time: Morgan et al. 30 8 ).
health-related quality of life
No studies reported outcomes using a validated health-related quality of life instrument.
diScuSSion
This Cochrane review identified seven RCTs (in 6,257 individuals) of interventions aimed at reducing dietary salt on mortality and CVD morbidity with follow-up of 6 months or longer. 19, 20, 30, 32, 33, 45, 51 We found no strong evidence that salt reduction reduced all-cause mortality or CVD morbidity in normotensives or hypertensives. A single RCT showed an increase in the risk of all-cause death in those with congestive heart failure receiving a low-sodium diet. 32 The interventions used were capable of reducing urinary sodium excretion and indicated that participants continued to comply with sodium restriction in the long-term, although, as noted in a previous Cochrane review, the degree of sodium restriction is likely to attenuate over time. 10 End of trial systolic and diastolic BPs were reduced by an average of some 1 mm Hg in normotensives and by an average of 2-4 mm Hg in hypertensives and those with heart failure. Sustained longterm reductions of BP of 1 and 4 mm Hg would be predicted to reduce CVD mortality by 5% and 20%, respectively. 58 Our point estimates are consistent with effects of this size but have wide CIs owing to the relatively small numbers of events.
comparison to previous reviews
Our finding of a lack of strong evidence of an effect of dietary sodium reduction on mortality and CVD outcomes is in contrast to those of Strazzullo and colleagues, who systematically reviewed prospective observational studies that examined the relationship between dietary sodium and all-cause mortality and CVD mortality. 6 They included 13 cohort studies over a follow-up of 3-17 years and found higher salt intake to be associated with a greater risk of stroke (pooled RR: 1.23, 95% CI: 1.06-1.43, 5,346 stroke events) and CVD events (pooled RR: 1.14, 95% CI: 0.99-1.32, 5,161 CVD events). Total and CVD mortality were not reported. However, an inherent limitation of this review is the observational nature of the evidence which is open to confounding. These studies describe the outcomes for people who choose to follow a low-salt diet but provide no information about what might happen if that diet were experimentally allocated. People who choose a lower-salt diet are likely to also eat a diet of fresh foods, lower in fats and refined carbohydrate, take more exercise and be less likely to smoke, so their lower levels of deaths and disease may not relate to salt intake at all.
Strengths and limitations
We comprehensively searched for RCTs of dietary sodium reduction of 6 months or more that reported mortality or CVD events. We attempted to contact all authors of included studies to verify events. Because of longer observational follow-up (up to 10-15-years) of three of the trials included in the previous Cochrane review (TOHP I 33,34 , TOHP II 34, 45 , and TONE 51 ) and inclusion of two more recent RCTs (Chang et al. 19 and Paterna et al. 32 ) we have been able to gather together more evidence on mortality and CVD outcomes (~6,250 participants, 665 deaths, 293 CVD events). Nevertheless the total amount of evidence on events remains relatively small. Assuming a control risk of 14% (Morgan et al. 30 ) some 2,500 CVD events would be required in order to detect a small reduction in RR (0.90) with dietary salt advice (at 80% power and 5% alpha). Our meta-analysis only had 10% power to detect a 10% reduction in RR.
Among all RCTs, only two of the seven included studies provided sufficient detail to be judged as having adequate random sequence generation, allocation concealment, and outcome blinding. 20, 51 Nevertheless, all trials provided evidence of baseline balance. Although lack of blinding is unlikely to alter outcome assessment when outcomes include mortality and CVD events, failure to blind participant may have led to a positive change in the lifestyle and dietary behaviors of control participants, reducing any difference between the groups.
Most trials appeared to be free from other dietary changes in the intervention and control groups apart from dietary sodium. The one major exception was the trial by Chang et al. where sodium was replaced by a high potassium substitute. 19 Potassium has beneficial effects on BP but may have deleterious effects in individuals with renal disease. 59 Two studies in hypertensives allowed changes in antihypertensive medication during the period of the trial. 30, 51 In both trials, lower levels of hypertensive medication in the intervention group compared to control may have reduced the BP-lowering effect of reduced dietary sodium and therefore offset mortality and CVD morbidity benefits.
In order to maximize the number of deaths and CVD events, we attempted to include data at the longest follow-up point. However, in doing so we may have introduced a major source of bias. For three large studies (TOHP I 33, 34 , TOHP II 34, 45 , and TONE 51 ) the longest follow-up was considerably beyond the official end of the trial. It was therefore unclear if the intervention groups continued their low-salt diets and whether control groups were left to continue with dietary advice or advised to reduce their salt. Furthermore, reporting of long-term nonprotocol-defined analyses may be prone to selective reporting of outcomes showing benefits and nonpublication of negative findings. For this reason, we included the primary analysis in each case as the latest data at trial end, which was more robust but showed slightly fewer deaths and CVD events.
implications for practice
Our findings are consistent with the belief that salt reduction is beneficial in normotensive and hypertensive people. However, the methods of achieving salt reduction in the trials included in our review, and other systematic reviews, were relatively
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Many countries have national authoritative recommendations, often sanctioned by government, that call for reduced dietary sodium. For example, in the UK, the National Institute of Health and Clinical Excellence (NICE) has recently called for an acceleration of the reduction in salt in the general population to a maximum intake of 6 g/day per adult by 2015 and 3 g by 2025. 1 Internationally, there are calls for a dietary salt reduction to be a major intervention for prevention and control noncommunicable diseases. 60 Voluntary reductions in hidden salt by the food industries and dietary advice to individuals are promoted as the best available interventions. Our review focuses on dietary advice and has not found robust evidence to support this approach.
implications for research
In accord with the research recommendation of a previous Cochrane review, three of the large trials (TOHP I 33, 34 , TOHP II 34, 45 , and TONE 51 ) have assessed the long-term effects of reduced dietary salt advice on mortality and CVD morbidity. 10 Our findings support the recent call for further rigorous large long-term RCTs, capable of definitively demonstrating the CVD benefit of dietary salt reduction. 5 Such trials need to incorporate population level interventions that are likely to lead to sustained reductions in salt intake commensurate with current guidelines. Further RCTs are needed to confirm if the dietary restriction of sodium is harmful for people with heart failure. It will be important to evaluate the effects of voluntary salt reductions by food industries as these may hold greater opportunities for practicable and inexpensive means of reducing salt intake in the population at large than focusing on dietary advice for individuals. 61 
